CMV-associated Immunomodulation in Renal Transplant Patients
ConditionKidney Transplantation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.
Eligibility criteria
Qualifiers
Age > 18 years
patients with end-stage renal failure programmed for kidney transplantation with a live donor
Age > 18 years
kidney transplant recipient with CMV viremia
Disqualifiers
Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion
patients receiving a desensitization protocol (ABO or anti-HLA)
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator
Source ClinicalTrials.gov